Active substance
Niclosamide
- SFDA 2
- US FDA 1
- WHO EML 1
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| TAENIAPASSIN TABLETS | 500 mg | Tablet · Oral use | 4 Blister | SAR 9.60 | NCE · Prescription | MERZ PHARMACEUTICAL | Withdrawn by MAH · Not Marketed |
| YOMESAN 0.5 G TAB | 500 mg | Tablet · Oral use | 4 Blister | SAR 10.70 | Generic · Prescription | BAYER PHARMA AG | Withdrawn by MAH · Not Marketed |
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| NICLOCIDE | 500MG | tablet, chewable · oral | BAYER PHARMS | Discontinued |
WHO WHO Model List of Essential Medicines (2025)
- 6.1.1. Intestinal anthelminthics · core
Hymenolepiasis; Diphyllobothriasis; Taeniasis due to Taenia saginata; Taeniasis due to Taenia solium
Oral > Solid: 500 mg tablet (chewable)
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.